The long-term complications of acute deep venous thrombosis (DVT) include recurrence, increased mortality, and the development of the postthrombotic syndrome. Rates of recurrent venous thromboembolism (VTE) are elevated in patients with cancer and thrombophilia. Heparin, administered either as unfractionated or low-molecular weight, is indicated for at least five days for acute DVT. Long-term treatment is currently a vitamin K antagonist with a variable duration depending on the etiology of the DVT and risk of bleeding. Novel anticoagulant agents that target factor Xa and directly inhibit thrombin are being studied in clinical trials and may one day replace vitamin K antagonists for the long-term treatment of VTE.
Interventional approaches such as percutaneous mechanical thrombectomy have the potential to reduce clot burden in acute DVT with lower bleeding risks and help prevent development of the postthrombotic syndrome, a common and potentially debilitating complication of DVT.
Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
2.
White RHThe epidemiology of venous thromboembolism. Circulation. 2003;107(23 suppl 1):14-18.
3.
White RH, Zhou H., Romano PSIncidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128:737-740.
4.
Buller HR, Agnelli G., Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):401S-428S.
5.
Qaseem A., Snow V., Barry P., et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2007;146:454-458.
6.
Goodacre S., Sampson F., Stevenson M., et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technol Assess. 2006;10(15):1-168,iii-iv.
7.
Fancher TL, White RH, Kravitz RLCombined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ. 2004;329(7470):821.
8.
Kearon C., Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism . N Engl J Med. 2003; 349: 631-639.
9.
Prandoni P., Lensing AW, Cogo A., et al. The long-term clinical course of acute deep venous thrombosis . Ann Intern Med. 1996;125:1-7.
10.
Hansson PO, Sorbo J., Eriksson H.Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-774.
11.
Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med . 2000;160:761-768.
12.
Kearon C.Long-term management of patients after venous thromboembolism. Circulation. 2004;110(9 suppl 1): 110-8.
13.
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.The Columbus Investigators . N Engl J Med.1997;337:657-662.
14.
Dolovich LR , Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000;160:181-188.
15.
Koopman MM, Prandoni P., Piovella F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682-687.
16.
Lensing AW, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med. 1995;155: 601-607.
17.
Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
18.
Goldhaber SZ, Buring JE, Lipnick RJ, et al. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med. 1984;76:393-397.
19.
Rogers LQ, Lutcher CLStreptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. Am J Med. 1990;88:389-395.
20.
Alesh I., Kayali F., Stein PDCatheter-directed thrombolysis (intrathrombus injection) in treatment of deep venous thrombosis: a systematic review. Catheter Cardiovasc Interv. 2007;70:143-148.
21.
Ouriel K., Gray B., Clair DG, et al. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol. 2000;11:295-298.
22.
Winter C., Weber H., Loeprecht H.Surgical treatment of iliofemoral vein thrombosis technical aspects. Possible secondary interventions. Int Angiol. 1989;8:188-193.
23.
Arko FR, Davis CM III , Murphy EH, et al. Aggressive percutaneous mechanical thrombectomy of deep venous thrombosis: early clinical results. Arch Surg.2007;142: 513-518; discussion 8-9.
24.
Decousus H. , Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998; 338:409-415.
25.
Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112:416-422.
26.
Ansell J.Vena cava filters: do we know all that we need to know? Circulation . 2005;112:298-299.
27.
Ridker PM, Goldhaber SZ, Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434.
28.
Linkins LA, Choi PT, Douketis JDClinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med . 2003;139:893-900.
29.
Hirsh J.Oral anticoagulant drugs. N Engl J Med. 1991 ;324:1865-1875.
30.
Eikelboom JW , Weitz JIA replacement for warfarin: the search continues . Circulation. 2007;116:131-133.
Kahn SR, Ginsberg JSRelationship between deep venous thrombosis and the postthrombotic syndrome . Arch Intern Med. 2004;164:17-26.
33.
Wille-Jorgensen P., Jorgensen LN, Crawford M.Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis. Thromb Haemost. 2005; 93:236-241.
34.
Ageno W., Piantanida E., Dentali F., et al. Body mass index is associated with the development of the post-thrombotic syndrome. Thromb Haemost. 2003;89:305-309.
35.
van Dongen CJ, Prandoni P., Frulla M., et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost. 2005;3:939-942.
36.
Kahn SR, Kearon C., Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost . 2005;3:718-723.
37.
Stain M., Schonauer V., Minar E., et al. The postthrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost. 2005; 3:2671-2676.
38.
Brandjes DP , Buller HR, Heijboer H., et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997; 349:759-762.
39.
Prandoni P. , Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the postthrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 2004;141:249-256.
40.
Ginsberg JS , Hirsh J., Julian J., et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med. 2001;161:2105-2109.
41.
Kolbach DN, Sandbrink MW, Hamulyak K., et al. Non-pharmaceutical measures for prevention of postthrombotic syndrome. Cochrane Database Syst Rev.2004 ; (1): CD004174.
